Efficacy and safety of adalimumab after failure of other anti-TNFα agents for plaque-type psoriasis: clinician behavior in real life clinical practice

Abstract

Introduction: During treatment with biologic agents for psoriasis (Pso) in a number of patients a failure may occur and discontinuation with transitioning to another drug or an optimization strategy, consisting in a dose-adjustment or a co-medication with a traditional systemic agent, represent two possible alternatives.

Objective: The SAFARI study objective was a retrospective observation of adalimumab efficacy and safety profile after switching from other anti-TNFα agents related to clinician behavior after the failure of the first-line agent.

Results: The retrospective multicenter observation demonstrated that after a first-line anti-TNFα failure adalimumab efficacy was consistent at week-12 and 24 with a further significant improvement at week-48 with a proportion of patients achieving PASI75/PASI90/PASI100 of 83.3, 71.6, and 56.9.%, respectively. Clinician strategies to extend drug-survival after first-line anti-TNFα failure, such as co-medication or dose-adjustment, were irrelevant to future drug effectiveness.

Conclusions: Adalimumab profile was excellent in this 5-year retrospective observation, showing the clinical validity of interclass transitioning among anti-TNFα options.

Keywords:

• Adalimumab
• anti-TNFα
• psoriasis
• switching

Disclosure statement

M. Esposito has served as a consultant, speaker and board member for Abbvie, Pfizer, Eli Lilly, Novartis, Biogen. F. Prignano has served as speaker/board member for Abbvie, Janssen-Cilag, Novartis, Eli-Lilly. K. Hansel has served as speaker/board member for Abbvie, Novartis; Pfizer. A. Zangrilli has served as a consultant, speaker and board member for Abbvie, Pfizer, Eli Lilly, Novartis. L. Bianchi has served as a consultant, speaker and board member for Abbvie, Celgene, Janssen, Novartis, Pfizer, UCB. L. Stingeni has served as a consultant, speaker and board member for Abbvie, Eli-Lilly, Novartis, Pfizer.